All News
RheumNow’s expanded coverage of the #ACR24 meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)
🚨 New SLE treatment update! 🚨 Dapirolizumab pegol (DZP), novel CD40L inhibitor, for moderate-to-severe lupus. Phase 3 trial, DZP reduced disease activity, helped taper steroids, and achieved a higher BICLA Safe and generally well tolerated! #ACR24 #L16 @rheumnow https://t.co/lFrKjz4CZ1
Bella Mehta bella_mehta ( View Tweet)
RheumNow’s expanded coverage of the #ACR24 Annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #ACR24 Annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty
Dr. John Cush RheumNow ( View Tweet)
#Publication #bias to Nth degree.
>1/3 of registered #postmeno #osteoporosis trials are NOT #published
👇search of trials
673 published
Vs
489 not published 890000 pts
MOSTLY when performed in the USA
No accountability for NOT publishing
#ACRbest #ACR24 @RheumNow #2122 https://t.co/UyMMbHhvvV
Janet Pope Janetbirdope ( View Tweet)
RheumNow’s expanded coverage of #ACR24 is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow & its faculty
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #ACR24 meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its Faculty.
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #ACR24 Annual meeting is sponsored in part by Novartis.All content is chosen by RheumNow & its faculty
Dr. John Cush RheumNow ( View Tweet)
US biosimilar exp
Interchangeable biosimilar - can substitute for reference product wo consulting MD
Primary endpt: pharmacokinetic data
61 approved biosimilars
@RheumKay: “pts should share in financial benefits”
Currently 5-87% discount
#PBMReform @ACRheumDC
@RheumNow #ACR24 https://t.co/RqwbZalZko
Links:
Eric Dein ericdeinmd ( View Tweet)
Quote of the day. “Time is kidney” Maria Dall’Era MD, UCSF at the ACR SLE guidelines for management of lupus nephritis @RheumNow #ACR24 https://t.co/rz9AhPS2cl
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
The updated 2024 ACR Guideline for Dx and Tx of #lupus nephritis is here!
Dr. Lisa Samaritano discusses the key recommendations 👇
For all pts: screen for LN, give HCQ and RAAS for pts with ⬆️ proteinuria
GCs in pts w/ LN class III/IV &/or V.
@Rheumnow #ACR24 @rheumarhyme https://t.co/wLVRGktR59
Links:
sheila RHEUMarampa ( View Tweet)
The overview for #lupus nephritis tx.
Triple therapy is preferred as first line due to:
1. RCTs (BLISS-LN & AURORA 1) showing improved outcomes w/ triple txs
2. Nephron loss happens with ongoing LN - time is kidney!
@RheumNow #ACR24 https://t.co/IQo3q3O1pt
Links:
sheila RHEUMarampa ( View Tweet)
Interesting! Study of pts w/ ANA(-) & dsDNA(+). 1 in 5 dx with APLS! Have others seen that?
I have been disgregarding this pattern, though some of that is related to my in-house assay (seems overly-sensitive) & my bias against overdiagnosis
#ACR24 @RheumNow Abstr#2391 https://t.co/FWgCjEwPDK
Mike Putman EBRheum ( View Tweet)
RheumNow’s expanded coverage of #ACR24 is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow & its faculty
Dr. John Cush RheumNow ( View Tweet)
#ACR24 Guidelines #LupusNephritis for refractory dz @RheumNow https://t.co/LlSixkggKK
TheDaoIndex KDAO2011 ( View Tweet)
#ACR24 - Featured Industry Presentations
Many of the great presentations for this meeting come from industry sponsored clinical trials and reports. Often these become the pivotal studies for regulatory approval and the annual congresses are their first look.… https://t.co/I6LMQ5xMUx https://t.co/UzTeqWUSdo
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #ACR24 meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty.
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #ACR24 Annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty
Dr. John Cush RheumNow ( View Tweet)
In this systematic review & metaanalyis by Dr. RFarhat et al, tacrolimus whole blood levels decrease in the 1st & 2nd trimesters then increase back to pre-pregnancy levels postpartum.
Needs further studies to guide dose adjustment.
@RheumNow #ACR24 abs1535 https://t.co/5MovzPJoFc
sheila RHEUMarampa ( View Tweet)
#HRT is not much of a risk of
Breast cancer
Compared to
A drink a day of #ETOH
#ACR24 @RheumNow @ACRheum https://t.co/LFgqbFocpb
Janet Pope Janetbirdope ( View Tweet)
